Results from our content library
AI-Powered Search
Sign in to search for any topic in our content library — get summaries, related past year questions, and practice MCQs on the topic.
Sign in to searchQdenga Dengue Vaccine Approval
The recent approval of the dengue vaccine Qdenga (TAK-003) by India’s Subject Expert Committee under the Drugs Controller General of India (DCGI) marks a significant advancement in combating dengue, a major public health concern. Developed by the Japanese pharmaceutical company Takeda, Qdenga is a tetravalent, live-attenuated vaccine designed to protect against all four dengue virus serotypes (DENV-1 to DENV-4).
Sign up free to read the full article
Access all current affairs, state notes, subject notes and more — completely free.
Qdenga (TAK-003) dengue vaccine approved by India's DCGI in April 2026. Tetravalent live-attenuated vaccine protects against all 4 dengue serotypes without pre-screening, advancing dengue prevention strategy.
Keywords